Biogen

BIIB NASDAQ
243.88
+11.40
+4.90%
After Hours: 242.80 -1.08 -0.44% 19:54 07/23 EDT
Open
239.00
Prev Close
232.48
High
246.99
Low
238.21
Volume
3.30M
Avg Vol (3M)
1.71M
52 Week High
388.67
52 Week Low
216.12
% Turnover
1.68%
Market Cap
47.97B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Biogen BIIB stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
MORE >

Recently

Name
Price
%Change